UCB and ImClone Systems have joined forces to develop CDP-791, an antibody targeting blood-vessel growth in tumors that recently passed Phase I trials. A Phase II study of the treatment is set to begin within weeks. The agreement calls for UCB and ImClone to share development costs -- and eventual profits -- equally. "This is an important milestone in the building of UCB's oncology franchise," stated Melanie Lee, executive vice president R&D for UCB.
- read this press release for more